CLCM
NBIX icon

Crawford Lake Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Crawford Lake Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-52,000
Closed -$4.04M – 88
2017
Q4 		$4.04M Buy
+52,000
New +$3.55M 0.95% 34

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Crawford Lake Capital Management's NBIX Position: Q1 2018 in Review

Crawford Lake Capital Management sold out of Neurocrine Biosciences (NBIX) in Q1 2018, closing a stake of 60,001 shares — an estimated $4.66M sold.

Crawford Lake Capital Management first reported a position in NBIX in Q2 2017 and held it in 2 quarters. The position peaked at $5.1M in Q2 2017. 267 funds tracked by Wall St. Rank hold NBIX as of Q1 2018.

  • Crawford Lake Capital Management reported no remaining Neurocrine Biosciences position as of Q1 2018 after selling out during the quarter.
  • Crawford Lake Capital Management sold 60,001 Neurocrine Biosciences shares in Q1 2018, an estimated $4.66M.
  • Crawford Lake Capital Management first reported a position in Neurocrine Biosciences in Q2 2017 and held it in 2 quarters.
  • Crawford Lake Capital Management's Neurocrine Biosciences position peaked at $5.1M in Q2 2017.
  • 267 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2018.

Based on Crawford Lake Capital Management's 13F filing for Q1 2018, filed 14 May 2018.